Lorcaserin Use in the Management of Morbid Obesity in a Pre-Liver Transplant Patient

Julio A. Gutierrez, Carmen Landaverde, Jennifer T. Wells, Fred Poordad

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Management of obesity and decompensated cirrhosis in those requiring liver transplantation (LT) is a challenging dilemma. Because of concerns for perioperative complications, many centers avoid transplant in those with a body mass index (BMI) greater than 40 kg/m2. Bariatric surgery is associated with increased risk attributable to complications of portal hypertension, including variceal rupture. Therefore, weight loss and LT options are limited. Several new classes of weight loss drugs are commercially available, including the anoretic, lorcaserin. This case illustrates the successful use of lorcaserin in a morbidly obese individual with decompensated cirrhosis evaluated for LT listing. (Hepatology 2016;64:301–302).

Original languageEnglish (US)
Pages (from-to)301-302
Number of pages2
Issue number1
StatePublished - Jul 1 2016

ASJC Scopus subject areas

  • Hepatology


Dive into the research topics of 'Lorcaserin Use in the Management of Morbid Obesity in a Pre-Liver Transplant Patient'. Together they form a unique fingerprint.

Cite this